Sanofi Announces Launch of AVAXIM® Junior in the UK for Active Immunisation Against Infection Caused by the Hepatitis A Virus in Children Aged 12 Months to 15 Years
READING, England–(BUSINESS WIRE)–Sanofi (EURONEXT: SAN and NASDAQ: SNY) has today announced the launch of AVAXIM® Junior in the UK, an inactive hepatitis A vaccine indicated for use in children aged 12 months to 15 years inclusive to prevent infection caused by the hepatitis A virus.1 The vaccination schedule consists of two vaccine doses injected by … [Read more…]
